| Project/Area Number |
16K09692
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Misawa Sonoko 千葉大学, 医学部附属病院, 准教授 (30375753)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | クロウ-深瀬症候群 / POEMS症候群 / 血管内皮増殖因子 / 形質細胞 / クロウ・深瀬症候群 / 診断基準 / 全国調査 / plasma cell dyscrasia / 内科 |
|---|
| Outline of Final Research Achievements |
Crow-Fukase (POEMS) syndrome is a rare cause of demyelinating neuropathy based on plasma cell dyscrasia. The prognosis of Crow-Fukase syndrome has been improved by application of treatment for myeloma. However, appropriate diagnostic criteria and disease severity are essential to establish efficient therapeutic strategies. Therefore, we have suggested a new diagnostic criteria, which was statistically validated and had high diagnostic accuracy. In addition, we analyzed prevalence rate and current treatment status, and prognosis of Crow-Fukase syndrome in Japan based on the national survey conducted in 2015. We are now considering disease severity based on our database, the national survey data, and national registry database.
|
| Academic Significance and Societal Importance of the Research Achievements |
クロウ-深瀬（POEMS）症候群は全国の患者数が400例未満の超稀少疾患である。患者数が少ないが故に、保険適用のある治療がなく、治療方針も標準化されていない。本研究により、現時点の我が国におけるクロウ・深瀬症候群の罹病者数、疾患プロファイル、治療の実態が明確になった。本症候群は骨髄腫の治療が奏功する可能性が高く、診断基準の整備、治療の標準化により、予後の改善が大いに期待される。本研究成果により、クロウ・深瀬症候群の今後の予後改善の基盤が築かれた。
|
